Study identifier:NIS-NBG-SER-2009/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Epidemiological study to describe approaches in diagnosis, treatment and social functioning of schizophrenic patients in Bulgaria
schizophrenia
-
No
-
All
440
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to provide accurate, reliable information on schizophrenia clinical management in order to detect unmet medical needs of this disease in terms of: • Patient characteristics. • Diagnostic and treatment approaches: initial and subsequent.
Location
Location
Sofia, Bulgaria
Location
Pazardzhik, Bulgaria
Location
Varna, Bulgaria
Location
Veliko Tarnovo, Bulgaria
Location
Vidin, Bulgaria
Location
Burgas, Bulgaria
Location
Stara Zagora, Bulgaria
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.